Pazopanib HCI

IUPAC name

5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride

CAS No.

635702-64-6

Molecular Weight

474.0 g·mol−1

Molecular Formula

C21H24ClN7O2S

Granule:    Available

Ready to press ‏þ

Ready to fill o

Mechanism Of Action:

Pazopanib is a second-generation multi-targeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumor blood vessel for tumor survival and growth.

Indication:

  •  First-line treatment of advanced renal cell carcinoma,
    Treatment of advanced renal cell carcinoma in patients who have had previous treatment with cytokine therapy.
  • Treatment of adult patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.